Pill study for advanced ovarian cancer that resists chemo
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests an experimental drug called sovilnesib (taken as a pill) for people with advanced ovarian, fallopian tube, or peritoneal cancer that has stopped responding to platinum chemo. The goal is to see if this drug can shrink or slow the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have a confirmed high-grade serous ovarian, fallopian tube, or primary peritoneal cancer that is advanced or has spread.
- Your cancer must have grown or returned within 6 months after platinum chemo, or you're unable to tolerate platinum chemo.
- You must have had prior treatment with bevacizumab (Avastin) unless you couldn't take it.
- You need at least one tumor that can be measured on a scan (CT or MRI).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial checks whether having surgery to remove as much tumor as possible, followed by ongoing targeted treatment, helps people with advanced ovarian (and related) cancers live longer and/or control cancer better. It specifically uses tumor-testing results to match patients and then continues treatment after surgery.
This study tests a new pill called INCB123667 for people with a type of ovarian cancer that has stopped responding to platinum chemotherapy. The goal is to see if the drug can shrink tumors or slow their growth.
This study tests a new drug (INCB123667) given as a pill, compared to standard chemotherapy, for people whose ovarian cancer has stopped responding to platinum-based treatments and whose tumor has high levels of a protein called Cyclin E1. The goal is to see if the new drug works better than standard chemo for this specific type of cancer.
This trial tests a new daily pill that targets a protein helping cancer cells divide. It may stop tumors from growing in people with advanced or metastatic cancer that has returned or stopped responding to standard treatments, including some types of ovarian, lung, and other solid tumors.
This trial tests a new pill called azenosertib (ZN-c3) for ovarian cancer that stopped responding to platinum chemotherapy. The drug targets tumors with high levels of the Cyclin E1 protein, and the goal is to see if it can shrink tumors or slow the cancer's growth.
This study tests a new drug called SYS6043, alone or with other treatments, for advanced solid tumors that have not responded to standard therapy. It may offer a new option for patients with certain types of ovarian, fallopian tube, or primary peritoneal cancer.
Hear when a new Fallopian Tube Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.